Skip to content 
Going public is a crucial step in the development of an enterprise. With Yingpai Pharmaceutical opening a new chapter in its growth, the number of pharmaceutical listed companies in the new district has increased to 10, accounting for nearly half of the city’s pharmaceutical enterprises’ “listing army”.
How did these enterprises manage to attract the attention of investors?
Why has Jiangbei consistently produced numerous listed companies?
01
Each enterprise has its unique skills.
The spotlight of the capital market is always shining on “hard power”.
Looking at the list of listed pharmaceutical companies in Jiangbei, this logical thread is equally clear: Each company has developed its own “special skills” in its own field.
The newly-listed Yingpai Pharmaceutical has already held a key technological advantage.
This “card” represents a new type of anti-cancer treatment that can be “precisely identified and targeted for elimination”. It can selectively kill cancer cells while minimizing the impact on normal tissues.
How strong is this “card”? The anti-cancer drug “Paisun®” launched by Yingpai Pharmaceutical is one of the only three PARP1/2 inhibitors approved for first-line maintenance treatment for the “entire population” of ovarian cancer in China. It has been included in the medical insurance. The team’s two innovative drugs were quickly noticed by overseas companies and they signed a global licensing cooperation deal worth nearly 1 billion US dollars.
With just “one card”, it opened the door to the capital market. And as the first company in the city to list on the STAR Market, Nanwei Medical also used a “small clamp” to drive the global market.
The company’s flagship product, “Harmony Clip”, not only overcomes the difficulty of traditional hemostasis clips in terms of operation, but also reduces the price to 1/8 of that of imported products. It has been hailed by many doctors worldwide as “the best clip in the world”, with annual sales of nearly 10 million units, generating several billion in revenue. Currently, Nanwei Medical’s products have covered over 6,000 hospitals across the country, and its business has expanded to over 90 countries and regions. According to the data, on average, 58 patients worldwide are using their products every minute.
By achieving excellence in specific fields, there will always be stories to tell:
Last year, Vitiligo Bio, which went public in Hong Kong, launched its core product LBL-024. This is the first candidate drug targeting the 4-1BB receptor to enter the registration clinical stage worldwide.
Yao Kang Biotechnology has established the world’s largest gene engineering mouse resource library, possessing nearly 30,000 gene engineering mouse models. It has achieved the “industry legend” of going public within just five years of its establishment.
The earlier-listed Jianyou Co., Ltd. on the Shanghai Stock Exchange is one of the largest suppliers of heparin raw materials in the world. Heparin preparations are exported overseas…
Capital is willing to “bet” with real money on high-quality enterprises and breakthrough innovations. In Jiangbei, there are always “powerful players” leading on various fronts.
02
Beyond the extraordinary skills, there is also the ecology.
Each enterprise attempts to pass the IPO hurdle based on its own capabilities. However, a number of enterprises frequently “emerge”, and this is inseparable from the continuous and profound ecological construction of a certain city.
In this ecosystem, the depth of industries is the most crucial “asset”.
Among the 10 listed companies, 8 are from the Biomedical Valley in the New District. Long Wangshan has witnessed every stage of their growth. Why have so many “seed players” been gathered here? Since its establishment, the Pharmaceutical Valley has been focusing on attracting projects in cutting-edge fields such as gene and cell therapy. As more than 1,300 enterprises have settled down, the industrial cluster has gradually become more robust, and naturally entered the “harvest period”.
In this ecosystem, professionalism and patience form the deeper foundation.
Among the cornerstone investors of Yingpai Pharmaceutical’s listing, apart from major capital players such as Tencent and Eli Lilly Asia Fund, there is also the state-owned capital of Jiangbei New District. During each round of financing during the critical development period of Vistali Life Sciences, the investment from the New District was always there. The New District has also innovatively established a foreign listing industrial investment fund with a total scale of 1 billion yuan, focusing on participating in the investment of enterprises in the new district that plan to go public overseas, such as Yuke Kang’an. It was with this “real money” support that Yuke Kang’an took a crucial step.
In this ecosystem, a gradient cultivation system is also indispensable. Here, there is the “Sparrow Plan” specifically designed for high-growth technology-based small and medium-sized enterprises, which can provide start-up funds and talent support to the start-up teams; as the team grows, new technologies need to be transformed into production, and the “Bone and Flesh Growth Plan” will promote quality enterprises to increase capital and expand production; even if you are the only one, the OPC community here also welcomes you with open arms, empowering every dream…
With soil, sunlight and rainwater, this powerful ecosystem has made the path beneath the enterprise increasingly smooth and clear.
03
Looking forward to more “the next one”
At this point, the two questions raised at the beginning have both been answered – enterprises rely on technology to establish themselves and use their products to communicate; the new zone supports itself with ecology and protects itself with services. This is why one good news follows another.
Of course, the enthusiasm of enterprises for going public through an IPO is still ongoing.
Yixi Biology, Zhengxiang Medicine, Nuining Biology… Since the second half of last year, the new district has also seen a number of enterprises “successively” file their IPO applications in Hong Kong. Among them, there are many outstanding leaders who have already taken the lead in their respective fields:
Two original drugs from Yingshui Biotech have attracted the attention of industry leader Fosun Pharmaceutical, which has invested heavily in their acquisition and has granted them an authorization value exceeding 1 billion yuan. Zhengxiang Medicine’s 1st-class anti-influenza new drug Jike Shu was approved for market launch in July last year and has been launched on the JD Health platform, becoming a “home-stay essential” for many people… These numerous innovative achievements have also sparked inquiries about “who will be the next listed company”.
